pharmaphorum
JUNE 7, 2024
Discover how compounding pharmacies use genetic information to create precision medications tailored to individual allergies. Learn how personalised treatments can benefit you.
Bio Pharma Dive
JUNE 7, 2024
A vote against MDMA-assisted therapy set back a high-profile treatment. Proponents argue the panel offered few solutions to longstanding problems, making the path forward unclear.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 7, 2024
The US Food and Drug Administration (FDA) has criticised the state of Chinese pharma company Jiangsu Hengrui’s facilities in a newly released 483 form.
Bio Pharma Dive
JUNE 7, 2024
After 34 years, Geron finally has an approved medicine in Rytelo. Elsewhere, Shionogi disclosed disappointing obesity drug data and AbbVie got some good trial news.
Pharmaceutical Technology
JUNE 7, 2024
Discover Curevac NV's groundbreaking patent for an mRNA-based RSV vaccine, targeting prophylaxis and treatment. Learn about the innovative pharmaceutical composition and method for stimulating a robust immune response against RSV.
Fierce Pharma
JUNE 7, 2024
Once hailed as an anti-aging magic bullet, telomerase has failed to live up to the hype as it was profiled in a | The FDA has approved Geron Corporation's Rytelo (imetelstat) to treat a group of bone marrow disorders called myelodysplastic syndrome (MDS). The approval is the first for the 33-year-old California biotech.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioSpace
JUNE 7, 2024
Both Eli Lilly and the partnered companies Boehringer Ingelheim and Zealand Pharma have mid-stage data readouts this week, fueling the race in metabolic dysfunction-associated steatohepatitis.
Pharmaceutical Technology
JUNE 7, 2024
Discover the groundbreaking patent by Syndax Pharmaceuticals Inc for compounds targeting menin-MLL interaction in leukemia treatment. Learn more about this innovative approach to fighting cancer.
BioSpace
JUNE 7, 2024
After rejecting a previous takeover offer from Future Pak, Vanda Pharmaceuticals is now fielding another acquisition proposal from Cycle Pharmaceuticals, which values the biotech at $8 per share.
Pharmaceutical Technology
JUNE 7, 2024
Discover Heidelberg Pharma AG's groundbreaking patent for synthesizing amanitin derivatives to treat breast, pancreatic, and colorectal cancer. Learn more about this innovative method now!
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioSpace
JUNE 7, 2024
Approved for patients with low- to intermediate-risk myelodysplastic syndromes, Geron’s Rytelo is the first telomerase inhibitor to hit the market and the company’s first approved drug after 34 years in business.
Pharmaceutical Technology
JUNE 7, 2024
Discover the groundbreaking patent by CSPC Pharmaceutical Group Ltd for a pharmaceutical composition targeting Cx43 hemichannels to treat inflammatory and neurodegenerative diseases like spinal cord injury. Explore the specific antibodies and stabilizing agents within a defined pH range.
BioSpace
JUNE 7, 2024
Biomea Fusion’s early-stage investigational diabetes treatment BMF-291 has been slapped with a full FDA clinical hold on its Phase I/II trials due to concerns over liver toxicity.
Pharmaceutical Technology
JUNE 7, 2024
Discover the innovative patent by Amneal Pharmaceuticals for a floating gastroretentive composition delivering sustained release of liothyronine. Revolutionizing hypothyroidism treatment with unique design and effective drug delivery.
BioSpace
JUNE 7, 2024
The companies announced Friday that their candidate survodutide, which is licensed to Boehringer Ingelheim from Zealand Pharma, improved fibrosis in more than 50% of treated patients with metabolic dysfunction-associated steatohepatitis.
Pharmaceutical Technology
JUNE 7, 2024
Discover how Allscripts Healthcare Solutions Inc's patented technologies optimize patient overviews in a user-friendly interface. Enhance workflow efficiency with customizable patient data displays.
BioSpace
JUNE 7, 2024
In advance of an advisory committee meeting on Monday, the FDA’s internal reviewers have raised issues regarding Eli Lilly’s Alzheimer’s disease candidate donanemab, flagging problems with its study design and safety outcomes.
Pharmaceutical Technology
JUNE 7, 2024
Discover the innovative patent by Zydus Lifesciences Ltd for a pharmaceutical oral suspension with mycophenolate mofetil, xanthan gum, and more. Revolutionizing immunosuppressive treatment methods.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
JUNE 7, 2024
Explore how commercialisation is the new frontier for digital innovation in the pharmaceutical industry, with a focus on GLP-1 drugs, digital strategies, and reducing patient acquisition costs.
Pharmaceutical Technology
JUNE 7, 2024
Discover Avadel Pharmaceuticals' innovative patent for modified release formulations of gamma-hydroxybutyrate, enhancing dissolution and pharmacokinetic properties. Learn about the unique composition designed for oral administration.
BioSpace
JUNE 7, 2024
AbbVie’s antibody-drug conjugate Elahere, developed by ImmunoGen, elicited a nearly 52% objective response rate in heavily pretreated patients with folate receptor-alpha-positive, platinum-sensitive ovarian cancer.
Pharmaceutical Technology
JUNE 7, 2024
The prognostic factor(s) driving outcomes at the initial stages of hepatocellular carcinoma remain unclear, complicating the treatment choice.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
JUNE 7, 2024
UK group Cycle Pharma has made an unsolicited takeover bid to buy Vanda Pharma, which is already fending off an overture from Future Pak.
Pharmaceutical Technology
JUNE 7, 2024
The FDA is looking to ask questions about a change of primary endpoint, treatment cessation and mortality reporting from the donanemab trial.
pharmaphorum
JUNE 7, 2024
Nestle Health Science bids to take control of Seres Therapeutics’ oral microbiome product Vowst for preventing C. diff infections.
Pharmaceutical Technology
JUNE 7, 2024
The company will be filing an IND for nicotinamide riboside chloride (NRC), which has received both orphan and rare pediatric designations.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
JUNE 7, 2024
Learn how building resilience can positively impact cancer trials in the field of oncology. Learn more about CancerEngage.
Pharmaceutical Technology
JUNE 7, 2024
Agomab Therapeutics has now secured a US Food and Drug Administration (FDA) orphan drug designation for IPF treatment AGMB-447.
Fierce Pharma
JUNE 7, 2024
After fessing up to wire fraud charges, a former Takeda employee will be preparing for a sentencing hearing rather than walking down the aisle with $2.3 million garnered through a scheme to defraud | Priya Bhambi, 40, pled guilty to wire fraud charges after running a detailed scheme to scam Takeda into paying for non-existent services from a fake consulting firm.
Pharmaceutical Technology
JUNE 7, 2024
The facility is expected to allow Orano Med to produce 5,000 doses of lead-212 based radioligand therapies by 2025.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Expert insights. Personalized for you.
69 
Let's personalize your content